Q3 Revenue Beat
Twist Bioscience Reports Strong Q3 Revenue Beat But Posts Wider Net Loss; Raises Full-Year Guidance
Anonymous
Key Points
1
Q3 2026 revenue was $118.38 million, up 23.3% year over year and beat consensus estimates by about 3.39%, but the company posted a net loss of $35.1 million or $0.56 per diluted share, continuing a pattern of EPS misses relative to consensus in the last four quarters.
2
Selling, general and administrative expenses rose to $80.7 million in the quarter, up from $63.4 million a year earlier, contributing to the quarterly loss despite strong top-line growth.
3
Insider trading activity has been heavy: 76 insider trades in the last six months with notable selling by CEO Emily M. Leproust (126,659 shares worth about $8.48 million) among other executives.
4
Analysts’ consensus at the time indicated a positive stance on the stock (8 Buy, 1 Hold, 0 Sell), with expectations that management commentary on the earnings call would influence the near-term outlook.
5
Twist scheduled an earnings conference call for 8:00 a.m. Eastern Time on Aug. 3, 2026, with a live webcast and dial-in details provided for analysts and investors to discuss the results.
Twist Bioscience posted fiscal third-quarter 2026 revenue of $118.4 million, up 23% from a year ago and ahead of Wall Street estimates — but shares fell 4.2% in pre-market trading after the company missed earnings expectations Yahoo Finance. The loss of $0.56 per diluted share came in 12 cents below the consensus estimate, extending a pattern of EPS misses for the synthetic DNA maker Watchlist News.
Revenue Hits $118M for 14th Straight Quarter of Growth
Twist reported $118.38 million in Q3 revenue, up from $96.06 million a year earlier, according to MarketScreener. That marks 14 consecutive quarters of year-over-year growth. The company shipped roughly 369,000 genes to about 2,650 customers during the quarter.
Revenue split into two main buckets. DNA Synthesis and Protein Solutions brought in $56.6 million, up 39% year over year. Next-Generation Sequencing Applications — tools that help read DNA — added $61.8 million, up 12%. Gross margin improved to 52.8%, up from 51.6% the prior quarter Yahoo Finance.
Rising Costs Drive Wider Loss Despite Strong Sales
Strong revenue did not translate to a smaller loss. Twist posted a net loss of $35.1 million for the quarter. Selling, general, and administrative expenses jumped to $80.7 million, up sharply from $63.4 million a year earlier Yahoo Finance. Those rising costs are the main reason the bottom line keeps missing targets even as sales grow.
The company reported an earnings surprise of -12%, missing the Zacks consensus estimate of -$0.50 per share Yahoo Finance. Analysts had expected the loss to narrow, but higher operating expenses pushed it wider instead.
Full-Year Guidance Raised, EBITDA Breakeven Targeted for Q4
Despite the EPS miss, Twist raised its full-year revenue guidance to a range of $456 million to $457 million. Management also reiterated a goal of reaching adjusted EBITDA breakeven — meaning revenue covering core operating costs — in the fourth quarter Watchlist News. The company held about $167 million in cash and equivalents at quarter's end.
Analysts remain broadly optimistic. At the time of reporting, 8 analysts rated the stock a Buy and just 1 rated it a Hold, with zero Sell ratings Yahoo Finance. Investors were closely watching the earnings call, held at 8:00 a.m. Eastern on August 3, 2026, for clues on how management plans to close the gap between revenue growth and profitability.
CEO Among Insiders Selling Millions in Stock This Year
Insider activity has drawn attention alongside the earnings report. Over the last six months, Twist insiders made 76 trades. CEO Emily M. Leproust sold 126,659 shares worth about $8.48 million Yahoo Finance. Other executives also sold shares during the period.
Insider selling does not always signal trouble — executives often sell shares for personal financial planning. But the volume of trades stands out at a time when the company is still reporting large quarterly losses and working toward its first EBITDA breakeven quarter MarketScreener.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
17
Articles
41
Reach
58
A
AnonymousAuthor